Melissa D Pinto1, Amy M Greenblatt2, Ronald L Hickman3,4, Heather M Rice3, Tami L Thomas5, John M Clochesy6. 1. Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia, USA. 2. Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. 3. Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio, USA. 4. Department of Anesthesiology and Perioperative Medicine, University Hospitals Case Medical Center, Cleveland, Ohio, USA. 5. NicoleWertheim College of Nursing and Health Sciences, Florida International University, Miami, Florida, USA. 6. School College of Nursing, University of South Florida, Tampa, Florida, USA.
Abstract
PURPOSE: To assess, from the young adults' (YAs') perspectives, the critical parameters (necessity, acceptability, feasibility, fidelity, and safety) of an avatar-based intervention, eSMART-MH, to reduce depressive symptoms. DESIGN AND METHODS: YAs (n = 60) were randomly assigned to eSMART-MH or control and observed for 12 weeks. Qualitative and quantitative data were collected. FINDINGS:Necessity, acceptability, fidelity, and safety of eSMART-MH were supported. Feasibility results were mixed. When benchmarked against usual care, eSMART-MH demonstrated greater feasibility. PRACTICE IMPLICATIONS: eSMART-MH is a promising digital therapeutic for depressive symptoms. Feasibility can be strengthened through "on the go" access via mobile devices and Internet delivery.
RCT Entities:
PURPOSE: To assess, from the young adults' (YAs') perspectives, the critical parameters (necessity, acceptability, feasibility, fidelity, and safety) of an avatar-based intervention, eSMART-MH, to reduce depressive symptoms. DESIGN AND METHODS: YAs (n = 60) were randomly assigned to eSMART-MH or control and observed for 12 weeks. Qualitative and quantitative data were collected. FINDINGS: Necessity, acceptability, fidelity, and safety of eSMART-MH were supported. Feasibility results were mixed. When benchmarked against usual care, eSMART-MH demonstrated greater feasibility. PRACTICE IMPLICATIONS: eSMART-MH is a promising digital therapeutic for depressive symptoms. Feasibility can be strengthened through "on the go" access via mobile devices and Internet delivery.
Authors: Manuela Ferrari; Judith Sabetti; Sarah V McIlwaine; Sahar Fazeli; S M Hani Sadati; Jai L Shah; Suzanne Archie; Katherine M Boydell; Shalini Lal; Joanna Henderson; Mario Alvarez-Jimenez; Neil Andersson; Rune Kristian Lundedal Nielsen; Jennifer A Reynolds; Srividya N Iyer Journal: Front Digit Health Date: 2022-04-07
Authors: Imogen C Rehm; Emily Foenander; Klaire Wallace; Jo-Anne M Abbott; Michael Kyrios; Neil Thomas Journal: Front Psychiatry Date: 2016-11-18 Impact factor: 4.157
Authors: Andreas Goreis; Anna Felnhofer; Johanna Xenia Kafka; Thomas Probst; Oswald D Kothgassner Journal: Front Neurosci Date: 2020-01-24 Impact factor: 4.677
Authors: Alaa A Abd-Alrazaq; Mohannad Alajlani; Nashva Ali; Kerstin Denecke; Bridgette M Bewick; Mowafa Househ Journal: J Med Internet Res Date: 2021-01-13 Impact factor: 5.428
Authors: Alaa Ali Abd-Alrazaq; Asma Rababeh; Mohannad Alajlani; Bridgette M Bewick; Mowafa Househ Journal: J Med Internet Res Date: 2020-07-13 Impact factor: 5.428